The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

por Coleman, R E, Winter, M C, Cameron, D, Bell, R, Dodwell, D, Keane, M M, Gil, M, Ritchie, D, Passos-Coelho, J L, Wheatley, D, Burkinshaw, R, Marshall, S J, Thorpe, H
Publicado 2010

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)

por Coleman, R.E., Collinson, M., Gregory, W., Marshall, H., Bell, R., Dodwell, D., Keane, M., Gil, M., Barrett-Lee, P., Ritchie, D., Bowman, A., Liversedge, V., De Boer, R.H., Passos-Coelho, J.L., O'Reilly, S., Bertelli, G., Joffe, J., Brown, J.E., Wilson, C., Tercero, J.C., Jean-Mairet, J., Gomis, R., Cameron, D.
Publicado 2018